STOCK TITAN

Biodexa Pharmaceuticals plc American Depositary Shs - $BDRX STOCK NEWS

Welcome to our dedicated page for Biodexa Pharmaceuticals plc American Depositary Shs news (Ticker: $BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals plc American Depositary Shs stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biodexa Pharmaceuticals plc American Depositary Shs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biodexa Pharmaceuticals plc American Depositary Shs's position in the market.

Rhea-AI Summary
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) appoints Ann Merchant as Non-executive Director to the Board of Directors. Ann Merchant brings extensive international operations experience from her roles at MorphoSys, Schreiner Medipharm, and Amgen. Dr. Stephen Parker, Chairman of Biodexa, expresses his excitement about Ann Merchant's appointment, highlighting her ability to bring a different perspective to the Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
management
-
Rhea-AI Summary
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) closes $6.0 million underwritten public offering and acquires exclusive, worldwide license to Tolimidone for Type I Diabetes clinical program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
-
Rhea-AI Summary
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced the pricing of an underwritten public offering of units, comprised of Class A and Class B Units, with each including Depositary Shares, Series E and Series F warrants. Ladenburg Thalmann & Co. Inc. is the sole book-running manager in connection with the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.54%
Tags
Rhea-AI Summary
Biodexa Pharmaceuticals PLC (BDRX) Acquires Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes. The company has entered into an agreement to develop and commercialize tolimidone, a potential treatment for type 1 diabetes. Tolimidone has shown encouraging signals of β cell proliferation in preclinical models and has an extensive safety database, having been exposed to approximately 700 patients in other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
83.15%
Tags
-
Rhea-AI Summary
Biodexa Pharmaceuticals PLC completes recruitment of cohort A in study of MTX110 in patients with recurrent glioblastoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary
Biodexa Pharmaceuticals PLC announces interim results for H1 2023, with total revenue of £0.30m and increased administrative expenses. The company raised $6.0m and $3.3m through private placements and completed enrollment of nine patients in a Phase I study. Net cash used in operating activities was £3.88m.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Biodexa Pharmaceuticals to present recruitment and treatment update in Phase 1 study of MTX-110 at EANO meeting. Three patients dosed, no dose-limiting toxicities observed. Encouraging progress for MTX-110 development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
conferences clinical trial
-
Rhea-AI Summary
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) Launches New Corporate and Clinical Trials Websites
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
-
Rhea-AI Summary
Biodexa Pharmaceuticals regains compliance with NASDAQ minimum bid price requirement. The company's securities will continue to be listed and traded on NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.18%
Tags
none
Rhea-AI Summary
Biodexa Ltd announces completion of enrolment and treatment in Phase 1 study of MTX110 for children with newly diagnosed diffuse midline gliomas (DMGs)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
Biodexa Pharmaceuticals plc American Depositary Shs

Nasdaq:BDRX

BDRX Rankings

BDRX Stock Data

4.06M
106.44M
10.26%
19.54%
1.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Abingdon

About BDRX

midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol’s lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech’s unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b